Raffaella Longarini

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women

Emilio Bajetta, Giuseppe Procopio, Luigi Celio et al. · Journal of Clinical Oncology · 2005 · 208 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Morano, Salvatore Corallo et al. · JAMA Oncology · 2019 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Joris van de Haar, Xuhui Ma, Salo Ooft et al. · Nature Medicine · 2023 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

Filippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile et al. · The Oncologist · 2015 · 50 citations · Full text

Medicine, Oncology, Pharmacology +13